- Home
- KBR vs JAZZ Comparison
KBR vs JAZZ Comparison
Compare KBR & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KBR
- JAZZ
- Stock Information
- Founded
- KBR 1901
- JAZZ 2003
- Country
- KBR United States
- JAZZ Ireland
- Employees
- KBR N/A
- JAZZ N/A
- Industry
- KBR Military/Government/Technical
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- KBR Industrials
- JAZZ Health Care
- Exchange
- KBR Nasdaq
- JAZZ Nasdaq
- Market Cap
- KBR 6.4B
- JAZZ 7.7B
- IPO Year
- KBR 2006
- JAZZ 2007
- Fundamental
- Price
- KBR $48.43
- JAZZ $126.78
- Analyst Decision
- KBR Buy
- JAZZ Strong Buy
- Analyst Count
- KBR 8
- JAZZ 14
- Target Price
- KBR $60.29
- JAZZ $178.93
- AVG Volume (30 Days)
- KBR 1.1M
- JAZZ 695.8K
- Earning Date
- KBR 10-22-2025
- JAZZ 11-05-2025
- Dividend Yield
- KBR 1.35%
- JAZZ N/A
- EPS Growth
- KBR 86.03
- JAZZ N/A
- EPS
- KBR 2.75
- JAZZ N/A
- Revenue
- KBR $8,047,000,000.00
- JAZZ $4,086,695,000.00
- Revenue This Year
- KBR $4.80
- JAZZ $5.65
- Revenue Next Year
- KBR $6.24
- JAZZ $5.79
- P/E Ratio
- KBR $17.75
- JAZZ N/A
- Revenue Growth
- KBR 12.31
- JAZZ 4.52
- 52 Week Low
- KBR $43.89
- JAZZ $95.49
- 52 Week High
- KBR $72.60
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- KBR 40.55
- JAZZ 57.18
- Support Level
- KBR $48.85
- JAZZ $123.88
- Resistance Level
- KBR $50.15
- JAZZ $129.50
- Average True Range (ATR)
- KBR 0.94
- JAZZ 3.02
- MACD
- KBR -0.25
- JAZZ -0.61
- Stochastic Oscillator
- KBR 5.37
- JAZZ 32.91
About KBR KBR Inc.
KBR, formerly Kellogg Brown & Root, is a global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company's business is organized into two segments: mission technology solutions and sustainable technology solutions. KBR has operations in over 30 countries and employs approximately 34,000 people. The firm generated $7.7 billion in revenue in 2024.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.